No Data
No Data
China Post Securities: The old-for-new policy has entered the implementation phase, and the medical devices sector is expected to enter a period of high performance growth.
It is expected that in December and the first quarter of 2025, various provinces will gradually implement the trade-in policy, relevant hospital tenders will be initiated, and equipment manufacturers are expected to see a large number of trade-in orders in the fourth quarter.
Wandong Medical Report for the Third Quarter of 2024
Beijing Wandong Medical Technology (600055.SH) released its performance for the first three quarters, with a net income of 0.116 billion yuan, a 3.7% year-on-year decrease.
Beijing Wandong Medical Technology (600055.SH) disclosed its third quarter report for 2024, achieving revenue in the first three quarters...
Beijing Wandong Medical Technology 2024 interim report.
Beijing Wandong Medical Technology's summary of the 2024 semi-annual report.
Beijing Wandong Medical Technology (600055.SH): net income of 84.7418 million yuan in the first half of the year, a year-on-year increase of 11.44%.
On August 16th, Gelonhui reported that Beijing Wandong Medical Technology (600055.SH) announced its 2024 semi-annual report, with operating income of 0.7 billion yuan and a year-on-year growth of 17.79%; net income attributable to shareholders of listed companies was 84.7418 million yuan, a year-on-year increase of 11.44%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 81.1167 million yuan, a year-on-year increase of 15.57%; and the basic earnings per share was 0.121 yuan. The company is headquartered in Peking and has two production bases in Peking and Suzhou, with business sectors involving large-scale imaging products, ultrasound diagnostic products, and imaging diagnostic services.
No Data
No Data